(Q37862836)

24 August 2017

1 reference

title

Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited: an ongoing story (English)

1 reference

24 August 2017

Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited: An ongoing story (English)

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

29 November 2024

0 references

0 references

Xavier Montalban

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21474190

29 November 2024

Ana Caminero

1 reference

24 August 2017

Manuel Comabella

series ordinal

1 reference

24 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21474190

29 November 2024

publication date

7 April 2011

1 reference

full work available at URL

24 August 2017

https://api.elsevier.com/content/article/PII:S016557281100066X?httpAccept=text/xml

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

https://api.elsevier.com/content/article/PII:S016557281100066X?httpAccept=text/plain

29 November 2024

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Journal of Neuroimmunology

29 November 2024

published in

1 reference

24 August 2017

volume

234

1 reference

24 August 2017

issue

1-2

1 reference

24 August 2017

page(s)

1-6

1 reference

Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

CNS demyelination during anti–tumor necrosis factor alpha therapy

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

The biology of cachectin/TNF--a primary mediator of the host response

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Aseptic meningitis in a patient taking etanercept for rheumatoid arthritis: a case report

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

An endotoxin-induced serum factor that causes necrosis of tumors

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Inflammatory demyelinating events following treatment with anti-tumor necrosis factor.

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Increased risk for demyelinating diseases in patients with inflammatory bowel disease.

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Tumor necrosis factor identified in multiple sclerosis brain

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

TNF accelerates the onset but does not alter the incidence and severity of myelin basic protein-induced experimental autoimmune encephalomyelitis

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Critical Points of Tumor Necrosis Factor Action in Central Nervous System Autoimmune Inflammation Defined by Gene Targeting

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Tumor necrosis factor-alpha antagonists: differential clinical effects by different biotechnological molecules

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

TNFalpha blockade in human diseases: an overview of efficacy and safety

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system.

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Regulated commitment of TNF receptor signaling: a molecular switch for death or activation.

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Autoimmune Diseases Induced by TNF-Targeted Therapies

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior?

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation.

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Anti?tumor necrosis factor therapy abrogates autoimmune demyelination

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Onset of multiple sclerosis associated with anti-TNF therapy

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Tumor necrosis factor-alpha antagonists and neuropathy

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG(35-55)-induced experimental autoimmune encephalomyelitis.

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Tumor necrosis factor receptor and Fas signaling mechanisms.

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

TNFalpha blockade in human diseases: mechanisms and future directions

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Target depletion of distinct tumor necrosis factor receptor subtypes reveals hippocampal neuron death and survival through different signal transduction pathways.

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

Tumor necrosis factor family ligand-receptor binding

29 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.JNEUROIM.2011.03.004

29 November 2024

Identifiers

1 reference

24 August 2017

1 reference